Association of Treatments for Myeloproliferative Neoplasms During Pregnancy With Birth Rates and Maternal Outcomes | Zendy

Dawn Maze | Zendy; Sajida Kazi | Zendy; Vikas Gupta | Zendy; Ann Kinga Malinowski | Zendy; Rouhi Fazelzad | Zendy; Prakesh S. Shah | Zendy; Nadine Shehata | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Association of Treatments for Myeloproliferative Neoplasms During Pregnancy With Birth Rates and Maternal Outcomes

Author(s) -

Dawn Maze,

Sajida Kazi,

Vikas Gupta,

Ann Kinga Malinowski,

Rouhi Fazelzad,

Prakesh S. Shah,

Nadine Shehata

Publication year - 2019

Publication title -

jama network open

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.278

H-Index - 39

ISSN - 2574-3805

DOI - 10.1001/jamanetworkopen.2019.12666

Subject(s) - medicine , miscarriage , pregnancy , essential thrombocythemia , systematic review , observational study , meta analysis , medline , aspirin , randomized controlled trial , obstetrics , pediatrics , polycythemia vera , genetics , political science , law , biology

Key Points Question Are use of aspirin, heparin, interferon, or combinations associated with live birth rate and adverse maternal outcomes in pregnant women with myeloproliferative neoplasms? Findings In this systematic review and meta-analysis of 22 studies, reporting on 1210 pregnancies, the live birth rate was 71.3%; most studies reported on pregnancy with essential thrombocythemia. The use of aspirin and interferon—but not heparin—was associated with higher odds of live birth. Meaning Moderate-quality evidence suggests that treatment with aspirin or interferon is associated with higher odds of live birth in pregnant patients with myeloproliferative neoplasms.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research